Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)

NCT04820842 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT04820842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04820842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)
Lead sponsor
Takeda
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2021
Completion date
November 3, 2021
Enrollment
26 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

narcolepsy type 1 (nt 1)